Methylene blue for chronic inactive hepatitis B
Treatments studied
Part of Infections clinical trials.
This trial tests whether a medication called methylene blue can help lower the amount of hepatitis B virus in people with a chronic but inactive infection. It may be an option for people whose virus levels are stable but not fully controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have chronic hepatitis B that is currently inactive (not causing liver inflammation).
- Your HBsAg level (a marker of the virus in your blood) is between 20 and 15,000 IU/mL and has been stable for at least 6 months.
- Your HBV DNA (viral load) is between 1,000 and 20,000 IU/mL and has been stable for at least 6 months.
- You are not currently taking any antiviral medications for hepatitis B (like tenofovir or entecavir).
- You do not have a G6PD deficiency, are not taking certain antidepressants, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This study tests a new drug called bepirovirsen for people with chronic hepatitis B. It aims to see if the drug works by checking liver tissue samples before and after treatment. Be aware it involves a liver biopsy.
Hear when a new Chronic HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.